{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:28:19Z","timestamp":1773509299313,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s43441-024-00634-5","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T22:01:16Z","timestamp":1711836076000},"page":"579-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-3455","authenticated-orcid":false,"given":"Barbara A.","family":"Hendrickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"McShea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"634_CR1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH E2A: clinical safety data management: definitions and standards for expedited reporting; 1994. https:\/\/database.ich.org\/sites\/default\/files\/E2A_Guideline.pdf."},{"key":"634_CR2","unstructured":"U.S. Food and Drug Administration. Investigational new drug safety reporting requirements for human drugs and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans: final rule; 2010. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2010-09-29\/pdf\/2010-24296.pdf."},{"key":"634_CR3","unstructured":"U.S. Food and Drug Administration. Guidance for industry and investigators: safety reporting requirements for INDs and BA\/BE studies; 2012. https:\/\/www.fda.gov\/media\/79394\/download."},{"issue":"9","key":"634_CR4","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-15-2082","volume":"22","author":"JP Jarow","year":"2016","unstructured":"Jarow JP, Casak S, Chuk M, et al. The majority of expedited investigational new drug safety reports are uninformative. Clin Cancer Res. 2016;22(9):2111\u20133.","journal-title":"Clin Cancer Res"},{"key":"634_CR5","unstructured":"US Food and Drug Administration. Draft guidance for industry: sponsor responsibilities\u2014safety reporting requirements and safety assessment for IND and bioavailability\/ bioequivalence studies; 2021. https:\/\/www.fda.gov\/media\/150356\/download. Accessed 10 Oct 2023."},{"key":"634_CR6","unstructured":"U.S. Food and Drug Administration (FDA). Draft guidance for industry: safety assessment for IND safety reporting; 2015. [Withdrawn]."},{"issue":"4","key":"634_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-021-00271-2","volume":"55","author":"BA Hendrickson","year":"2021","unstructured":"Hendrickson BA, Wang W, Ball G, et al. Aggregate safety assessment planning for the drug development life-cycle. Ther Innov Regul Sci. 2021;55(4):717\u2013732.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"634_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40290-023-00470-2","volume":"37","author":"BA Hendrickson","year":"2023","unstructured":"Hendrickson BA, Agarwal A, Bennett D, et al. Value and implementation of the aggregate safety assessment plan. Pharm Med. 2023;37(3):171\u201381.","journal-title":"Pharm Med"},{"key":"634_CR9","unstructured":"Council for International Organizations of Medical Sciences. Management of safety Information from clinical trials\u2014report of CIOMS working group VI. Geneva, Switzerland: CIOMS; 2005."},{"key":"634_CR10","unstructured":"U.S. Food and Drug Administration. FDA Medical Queries (FMQ) posted as draft Sept 26, 2022: docket and document available online: https:\/\/www.regulations.gov\/document\/FDA-2022-N-1961-0001. Accessed 10 Oct 2023."},{"key":"634_CR11","unstructured":"U.S. Food and Drug Administration. Draft guidance for industry: meta-analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products; 2018. https:\/\/www.fda.gov\/media\/117976\/download."},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.cct.2011.05.010","volume":"32","author":"G Ball","year":"2011","unstructured":"Ball G, Piller L, Silverman M. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemp Clin Trials. 2011;32:S2\u201317.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"634_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/2168479016656702","volume":"50","author":"P Schnell","year":"2016","unstructured":"Schnell P, Ball G. A Bayesian exposure-time method for clinical trial safety monitoring with blinded data. Ther Innov Regul Sci. 2016;50(6):833\u201345.","journal-title":"Ther Innov Regul Sci"},{"key":"634_CR14","volume-title":"Statistical applications from clinical trials and personalized medicine to finance and business analytics","author":"G Ball","year":"2016","unstructured":"Ball G, Schnell P. Blinded safety signal monitoring for the FDA IND reporting final rule. In: Statistical applications from clinical trials and personalized medicine to finance and business analytics. Cham: Springer; 2016."},{"key":"634_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/pst.1898","volume":"17","author":"S Mukhopadhyay","year":"2018","unstructured":"Mukhopadhyay S, Waterhouse B, Hartford A. Bayesian detection of potential risk using inference on blinded safety data. Pharm Stat. 2018;17:823\u201334.","journal-title":"Pharm Stat"},{"key":"634_CR16","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s43441-020-00183-7","volume":"54","author":"E Goren","year":"2020","unstructured":"Goren E, Lin L, Blaustein R, et al. Bayesian meta-analysis of safety outcomes using blinded clinical trial data. Ther Innov Regul Sci. 2020;54:1557\u201365.","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"634_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/pst.2278","volume":"22","author":"K Brock","year":"2022","unstructured":"Brock K, Chen C, Ho S, et al. A Bayesian method for safety signal detection in ongoing blinded randomized controlled trials. Pharm Stat. 2022;22(2):378\u201395.","journal-title":"Pharm Stat"},{"issue":"2","key":"634_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/pst.2175","volume":"21","author":"B Waterhouse","year":"2022","unstructured":"Waterhouse B, Hartford A, Mukhopadhyay S, et al. Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation. Pharm Stat. 2022;21(2):372\u201385.","journal-title":"Pharm Stat"},{"issue":"3","key":"634_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/19466315.2015.1043395","volume":"7","author":"J Wittes","year":"2015","unstructured":"Wittes J, Crowe B, Chuang-Stein C, et al. The FDA\u2019s final rule on expedited safety reporting: statistical considerations. Stat Biopharm Res. 2015;7(3):174\u201390.","journal-title":"Stat Biopharm Res"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-024-00634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-024-00634-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-024-00634-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:06:56Z","timestamp":1718219216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-024-00634-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1007\/s43441-024-00634-5","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BAH has AbbVie stock options. GB reports personal fees from consultancy for pharmaceutical industry outside the submitted work. CM is an employee of UCB Biosciences outside the submitted work. ST is an employee of Amgen Inc. outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}